Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.47 |
| ▸ | SMO | Q99835 | 2/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | MTTP | P55157 | 2/20 | 0.41 |
| ▸ | APOB | P04114 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492058 | 0.89 | HTR2C (0.50) | TRPV1SMORHOANR3C1MTTP | |
| SCHEMBL6487662 | 0.88 | TRPV1 (0.49) | TRPV1SMONR3C1MTTPAPOB | |
| SCHEMBL6503188 | 0.88 | NPC1 (0.45) | KDM4ENPC1MITFPKMRAB9A | |
| SCHEMBL6500685 | 0.87 | TRPV1 (0.48) | TRPV1SMONR3C1MTTPAPOB | |
| SCHEMBL6500678 | 0.87 | TRPV1 (0.48) | TRPV1SMONR3C1MTTPAPOB | |
| SCHEMBL6487840 | 0.87 | TRPV1 (0.48) | TRPV1SMONR3C1MTTPAPOB | |
| SCHEMBL6501432 | 0.87 | ITGB1 (0.42) | TRPV1 | |
| SCHEMBL6488986 | 0.86 | TRPV1 (0.49) | TRPV1SMONR3C1MTTPAPOB | |
| SCHEMBL6488729 | 0.86 | TRPV1 (0.51) | TRPV1SMONR3C1MTTPAPOB | |
| SCHEMBL6490538 | 0.83 | CHRNB2 (0.38) | SMOMTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | TRPV1 2245/4885SMO 2580/4885RHOA 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.